D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)
D. Boral Capital has reiterated a "Buy" rating for Humacyte (NASDAQ:HUMA) with a price target of $25.00, despite the company's current unprofitability and a mixed analyst consensus of "Moderate Buy" with an average price target of $8.14. Humacyte, a clinical-stage biotech developing regenerative human acellular vessels, opened trading at $1.08, down 5.3%, with institutional investors actively modifying their holdings in the company.
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
Humacyte, Inc. presented long-term safety and efficacy results for its Symvess® bioengineered human tissue in extremity arterial trauma patients at the Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society. The data showed that after up to 36 months of follow-up, Symvess maintained high rates of limb salvage, low infection rates, and no unprovoked structural failures. These results highlight Symvess's potential as a durable and effective solution for trauma patients when autologous vein grafts are not feasible.
Humacyte Announces Presentation of Symvess Long-Term Safety and Efficacy Results at VESS Meeting
Humacyte, Inc. presented long-term safety and efficacy results for Symvess in extremity arterial trauma patients at the VESS Meeting. The data, spanning up to 36 months, showed high rates of limb salvage, low infection rates, and no structural failures for Symvess, highlighting its durability and potential as an alternative when autologous vein grafts are not feasible. Symvess maintained structural integrity and consistent diameter, reinforcing its benefits for severe trauma injuries.
Humacyte Shares Surge on US Defense Funding News
Humacyte Inc.'s shares saw a significant jump of 28% following news of substantial funding from the US Department of Defense for its biologic vascular repair technologies, specifically the Symvess bioengineered blood vessel product. This funding, part of the 2026 US Department of Defense Appropriations Act, has generated positive market sentiment despite the company's existing financial challenges. Analysts maintain a bullish outlook, recognizing the potential for market expansion and strategic financing to drive future growth.
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts
Humacyte, Inc. (NASDAQ:HUMA) has received an average "Moderate Buy" recommendation from eight analysts, with seven issuing a buy rating and one a sell rating. The average 12-month price target is set at $8.14. Shares are currently trading around $1.01, with institutional ownership nearing 44.7% following recent stake increases by major firms.
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Battlefield Vascular Repair Potential
Humacyte (HUMA) is under investor scrutiny after the U.S. Department of Defense earmarked funding for biologic vascular repair technologies, causing a significant short-term surge in its stock price. Despite a 70.46% decline over the past year, current analysis suggests Humacyte is 94.7% undervalued with a fair value of $22.83, far exceeding its current trading price of $1.22. This optimistic valuation hinges on rapid revenue expansion, a swing to profitability, and successful uptake of its ATEV in dialysis access and its coronary tissue engineered vessel in CABG.
Why Humacyte (HUMA) Is Up 5.1% After New DoD Funding Backs Symvess Trauma Use
Humacyte (HUMA) saw a 5.1% increase following the announcement of new U.S. Department of Defense (DoD) funding for its bioengineered blood vessel, Symvess, for traumatic extremity vascular injuries. This funding, part of the Fiscal Year 2026 Appropriations Act, validates the potential of Symvess as an off-the-shelf solution for battlefield trauma. Despite this positive development, the company still faces challenges related to limited revenue and ongoing cash burn, with future revenue and earnings projections showing significant growth by 2028.
Humacyte (NASDAQ:HUMA) Earns "Buy" Rating from D. Boral Capital
D. Boral Capital has reiterated a "Buy" rating for Humacyte (NASDAQ:HUMA) with a $25 price objective, contributing to an overall "Moderate Buy" consensus among analysts, who have a collective price target of $8.14. Shares of Humacyte recently surged by 28.4% to $1.21, giving the clinical-stage biotech a market capitalization of $225.7 million. The company is focused on developing regenerative human acellular vessels (HAVs) for vascular access and repair, with its lead product showing promise in clinical trials.
Humacyte says new U.S. law backs bioengineered vessels (HUMA)
Humacyte's stock surged by approximately 27% after the company announced that the U.S. Congress passed new legislation. This law provides funding for the procurement of human-derived bioengineered vessels, directly supporting products like Humacyte's lead product, Symvess vascular conduit. The development is a significant positive for the Durham, North Carolina-based biotech firm.
Humacyte stock jumps after securing DoD funding for vascular repair tech
Humacyte Inc. (NASDAQ:HUMA) saw its stock jump after announcing that the U.S. Department of Defense's FY 2026 Appropriations Act includes dedicated funding for its bioengineered vascular repair technologies. This federal investment aims to support the evaluation and incorporation of biologic vascular repair technologies for military personnel with traumatic vascular injuries. Humacyte's Symvess is the sole FDA-approved human-derived bioengineered blood vessel on the market and has shown promising results in treating wartime injuries in Ukraine.
HUMA Stock Just Shot Up 12% Today – Here’s Everything To Know About The DOD Funding Fueling The Surge
Humacyte Inc. (HUMA) shares surged nearly 12% on Monday following the announcement that the FY2026 U.S. Department of Defense (DOD) Appropriations Act includes funding for the procurement of bioengineered blood vessels. This funding is specifically for evaluating and incorporating biologic vascular repair technologies for warfighters with traumatic vascular injuries. Humacyte's product, Symvess, is noted as the only human-derived bioengineered blood vessel approved by the FDA.
Pentagon backs lab-grown blood vessels for wounded troops
Humacyte (Nasdaq: HUMA) announced that the FY2026 U.S. Department of Defense (DoD) appropriations include funding for its bioengineered blood vessels, Symvess, for treating traumatic extremity arterial injuries in warfighters. Symvess is the only human-derived, FDA-approved bioengineered blood vessel, and a retrospective study in Ukraine found 100% survival and zero amputations in 16 treated patients. Despite potential safety risks like graft failure and thrombosis, this funding signifies significant government backing for the company's innovative technology, leading to a 9.60% stock increase.
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
Humacyte, Inc. announced new U.S. Department of Defense (DoD) funding for the procurement of its bioengineered blood vessels, Symvess®. This funding, part of the FY 2026 DoD Appropriations Act, supports the evaluation and integration of biologic vascular repair technologies for warfighters with traumatic vascular injuries. Symvess is the only human-derived bioengineered blood vessel approved by the FDA for extremity arterial injury and has shown positive results in humanitarian use in Ukraine.
Humacyte stock jumps after securing DoD funding for vascular repair tech
Humacyte Inc. (NASDAQ:HUMA) saw its stock surge by 11.4% after announcing that the U.S. Department of Defense's FY 2026 Appropriations Act includes dedicated funding for its bioengineered vascular repair technologies. This investment aims to integrate biologic vascular repair technologies for military personnel with traumatic vascular injuries, supporting Humacyte's Symvess which is the only FDA-approved human-derived bioengineered blood vessel on the market. The product has already shown promising results in treating wartime injuries in Ukraine.
Humacyte set to unveil advances in vascular surgery innovation
Humacyte is preparing to showcase significant developments in its Symvess™ acellular tissue-engineered vessel during February and March events. The company aims to foster innovation, education, and collaboration within vascular surgery. These presentations will highlight the scientific progress and practical applications of Humacyte's technology to surgical communities.
Humacyte, Inc. (HUMA) Stock Analysis: Biotechnology Innovator with a 648% Potential Upside
Humacyte, Inc. (HUMA) is a biotech company focused on developing bioengineered human tissues called implantable human acellular vessels (HAVs) for various therapeutic uses. Despite current financial challenges typical of early-stage biotech, analysts are optimistic, projecting a 648% potential upside. The company's stock is currently in oversold territory, making it a high-risk, high-reward opportunity for investors interested in cutting-edge medical technology.
Humacyte stock slides on pricing public offering of units to raise $50M
Humacyte's stock declined after the announcement of its public offering of units, aiming to raise $50 million. The offering includes common stock and warrants, with proceeds intended for clinical trials, manufacturing, and general corporate purposes.
Humacyte (HUMA) Valuation Check As Financing And Israel Filing Plans Lift Investor Interest
Humacyte (HUMA) is gaining investor attention due to recent financing news, plans to retire debt, and a marketing application for its acellular vessel product in Israel. While the stock has seen recent price and volume jumps, it follows a period of significant losses over the past year. Analysts currently view Humacyte as undervalued, with a fair value of $22.83, based on assumptions of steep revenue acceleration and improved future earnings.
Humacyte (HUMA) Valuation Check As Financing And Israel Filing Plans Lift Investor Interest
Humacyte (HUMA) is gaining investor interest due to recent financing news, debt retirement plans, and a planned marketing application in Israel for its acellular vessel product. Despite previous stock declines, a Simply Wall St valuation suggests Humacyte could be 95.4% undervalued, with a fair value of $22.83 against a current price of $1.05. This bullish outlook, however, relies on assumptions of accelerated product uptake and successful trial progress, highlighting the need for investors to consider associated risks.
Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Moderate Buy" by Analysts
Eight analysts have issued ratings for Humacyte, Inc. (NASDAQ:HUMA), resulting in an average recommendation of "Moderate Buy" with a 12-month average price target of $8.14. Institutional investors have also adjusted their holdings, with Vanguard Group Inc. and CenterBook Partners LP significantly increasing their stakes. Humacyte reported an earnings beat in its last quarterly results, though revenue missed expectations, and the company is a clinical-stage biotech developing off-the-shelf human acellular vessels.
While institutions invested in Humacyte, Inc. (NASDAQ:HUMA) benefited from last week's 10% gain, retail investors stood to gain the most
Retail investors hold the largest stake in Humacyte, Inc. (NASDAQ:HUMA) at 59%, meaning they benefited most from the recent 10% market cap gain. Institutions own 24% of the company, with Fresenius Medical Care AG being the largest single shareholder. The article emphasizes that while institutional ownership provides credibility, it's crucial to look at other factors like earnings history and analyst forecasts, and warns of potential risks.
Humacyte, Inc. (HUMA) Stock Analysis: Unveiling a Potential 571.55% Upside in the Biotech Sector
Humacyte, Inc. (NASDAQ: HUMA) is a biotechnology company focused on developing bioengineered human tissues, particularly human acellular vessels (HAVs). Despite its early stage with negative earnings and free cash flow, analysts show high optimism with six buy ratings and one hold rating, projecting a potential upside of 571.55% from its current price of $1.17 to an average target of $7.86. Investors are advised to conduct thorough due diligence while considering its high growth potential in addressing unmet medical needs.
Today's Analyst Ratings: Humacyte (HUMA) Maintains "Buy" Rating
D. Boral Capital has maintained a "Buy" rating for Humacyte (HUMA) with an unchanged price target of $25.00, according to analyst Jason Kolbert. This continues a consistent trend of positive ratings and price targets from multiple analysts for the biotech company. The average target price from 7 analysts is $7.86, suggesting a potential upside of 554.76% from its current price of $1.20, with an "Outperform" consensus recommendation.
Preventable surgery complications can drive hospital charges toward $600K
Humacyte (Nasdaq: HUMA) released a five-year retrospective analysis showing that preventable complications from extremity arterial injuries, such as graft infection and amputation, can add nearly $600,000 to hospital charges, significantly exceeding initial repair costs. The company highlights its product, Symvess, as an off-the-shelf biologic conduit that has demonstrated lower rates of infection and amputation compared to historical controls for these types of injuries. This data underscores the economic burden of such complications and positions Symvess as a potential cost-saving and outcome-improving solution.
Humacyte rises on Symvess sale to military treatment facility
Humacyte's shares rose after the company announced its Symvess bioengineered vessel was sold and implanted at a military treatment facility. This marks an important step for the product, following its U.S. FDA approval in late March.
Humacyte plans to seek approval for vessel product in Israel
Humacyte, Inc. (NASDAQ:HUMA) announced plans to file a Marketing Authorization Application with the Israel Ministry of Health for its acellular tissue engineered vessel, Symvess, in the first quarter of 2026. This move follows requests from Israeli surgeons and aims to expand the company's global presence after FDA approval in December 2024. Despite challenges like negative EBITDA and cash burn, the company's Q3 2025 earnings beat expectations, and it has secured a new credit facility for $77.5 million.
HUMA - Humacyte Inc Latest Stock News & Market Updates
This page provides the latest news and market updates for Humacyte Inc. (NASDAQ: HUMA), a clinical-stage biotechnology company focused on developing bioengineered human tissues. Investors can find information on clinical advancements, regulatory milestones, strategic developments, and financial results, including details on Symvess® and upcoming presentations. The article highlights recent activities such as marketing authorization applications, publication of long-term study results, and financial updates.
Humacyte announces planned MAA for Symvess in Israel
Humacyte (HUMA) plans to file a Marketing Authorization Application (MAA) for its acellular tissue engineered vessel, Symvess, with the Israel Ministry of Health in Q1 2026. The company anticipates a 120-working-day review period due to existing FDA approval. This initiative is supported by Israeli surgeons who participated in the Symvess vascular trauma trial.
D. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA)
D. Boral Capital has reiterated a "Buy" rating for Humacyte (NASDAQ:HUMA) with a $25.00 price objective, despite mixed analyst views and a consensus "Moderate Buy" rating with a target of $8.29. Humacyte's stock currently trades around $0.98, and the clinical-stage biotech is focused on developing off-the-shelf regenerative human acellular vessels.
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
Humacyte, Inc. (Nasdaq: HUMA) announced its plan to file a Marketing Authorization Application (MAA) with the Israel Ministry of Health for approval of Symvess® for arterial trauma repair in Q1 2026. This move is driven by requests from Israeli surgeons and hospitals, and the company expects an expedited review process due to existing FDA approval. Humacyte also anticipates expanding Symvess® into other international territories, including Europe and the Middle East, leveraging the FDA approval for faster commercialization.
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
Humacyte, Inc. announced its plan to file a Marketing Authorization Application (MAA) for Symvess® (acellular tissue engineered vessel) in Israel during the first quarter of 2026 for arterial trauma repair. This expansion into Israel is based on requests from surgeons and hospitals and follows the recent FDA approval of Symvess. The company also anticipates broader global expansion into Europe and the Middle East, leveraging expedited commercialization pathways enabled by FDA approval.
Off-the-shelf blood vessel implant helps save injured limbs in study
Humacyte has published long-term safety and efficacy data for its Symvess® bioengineered blood vessel in extremity trauma repair. The study shows high limb salvage rates (87.3% at 12 months, 82.5% at 24 months) and notably low infection rates (92.9% infection-free from months 3-36) with no spontaneous structural failures over 36 months, offering a critical off-the-shelf solution for severe vascular injuries. Despite positive clinical outcomes, the company's stock, HUMA, experienced a moderate negative market reaction.
Humacyte's (HUMA) Buy Rating Reaffirmed at D. Boral Capital
D. Boral Capital has reaffirmed a "buy" rating on Humacyte (NASDAQ:HUMA) with a $25.00 price objective, although the average analyst target on MarketBeat is $8.29. Humacyte is a clinical-stage biotechnology company developing regenerative human acellular vessels, and its stock is currently trading around $1.14 with a market capitalization of approximately $212.55 million. The company recently beat quarterly EPS estimates but missed revenue forecasts.
Lab-Grown Blood Vessel Maker Promotes Risky Off-Label Uses
Humacyte, a biotechnology firm, is promoting off-label uses of its artificial blood vessel, Symvess, beyond its FDA-approved scope for trauma to limbs, despite known safety risks and questionable efficacy. The company's actions, including presentations at a vascular surgery conference, have raised ethical and regulatory concerns, particularly given the product's potential for catastrophic ruptures and financial pressures on Humacyte. Shareholder lawsuits and former FDA officials criticize Humacyte for allegedly concealing risks and misleading investors about the device's true success rates.
Humacyte announces credit facility of $77.5M with Avenue Capital
Humacyte (NASDAQ: HUMA) has secured a $77.5 million credit facility from an affiliate of Avenue Capital Group. This financing includes an initial $27.5 million term loan, with the potential for an additional $50 million. The funds are earmarked to support the ongoing clinical and commercial development of Humacyte's bioengineered human acellular vessel (HAV) for various vascular repair and reconstruction applications.
Humacyte enters sales agreement with TD Securities
Humacyte has executed a new at-the-market (ATM) sales agreement with TD Securities. This agreement allows the company to sell shares of its common stock having an aggregate offering price of up to $75 million. The move aims to strengthen Humacyte's financial position and provide capital for future operations.
Humacyte's US$28m Market Cap Fall Books Insider Losses
Insiders at Humacyte (NASDAQ: HUMA) who purchased US$146.1k worth of stock over the last year at an average price of US$1.38 have seen their investment decrease to US$118.7k due to a recent 12% price decline. Despite the losses, past insider purchases, including a US$66k transaction by Kathleen Sebelius at US$1.32 per share, suggest a belief in the company's future value. Insiders currently own 6.1% of the company, aligning their interests with other shareholders.
Humacyte announces credit facility of $77.5M with Avenue Capital
Humacyte has announced a new credit facility worth $77.5 million with Avenue Capital. This financial arrangement will support the company's operations and strategic initiatives. The facility is expected to provide substantial capital for Humacyte's ongoing projects.
Humacyte's US$28m Market Cap Fall Books Insider Losses
Insiders of Humacyte, Inc. who purchased shares in the past year at an average price of US$1.38 are now facing losses due to a recent 12% stock price decline, reducing their initial US$146.1k investment to US$118.7k. Despite these losses, the fact that notable purchases were made at prices above the current US$1.12 suggests confidence in the company's future, and insiders collectively own 6.1% of the company. However, the article also advises examining potential warning signs for Humacyte.
Humacyte secures up to $77.5 million credit facility with Avenue Capital
Humacyte, Inc. (NASDAQ:HUMA) has secured a credit facility of up to $77.5 million with Avenue Venture Opportunities Fund II, L.P., providing crucial non-dilutive financing. This agreement includes an initial $40 million fully funded at closing to retire existing debt, with an additional $37.5 million available based on revenue, regulatory approval, and liquidity. The biotechnology company, which recently received FDA approval for its Symvess product, is positioning itself for expanded market use and further clinical trials despite recent cash burn challenges.
Humacyte secures up to $77.5 million credit facility with Avenue Capital
Humacyte, Inc. (NASDAQ:HUMA) has secured a credit facility of up to $77.5 million with Avenue Venture Opportunities Fund II, L.P., providing crucial non-dilutive financing. An initial $40 million has been funded to retire existing debt, with an additional $37.5 million available upon meeting specific conditions. This move comes as the biotechnology company aims to expand the use of its Symvess product and navigate significant cash burn challenges.
Humacyte Terminates Revenue Interest Agreement
Humacyte (HUMA) has terminated its Revenue Interest Purchase Agreement and Option Agreement with TPC Investments, agreeing to pay $38 million in cash and issue over 5.7 million shares. This strategic move is expected to impact Humacyte's financial operations, with the cash payment funded by a new credit facility. While an analyst maintains a "Buy" rating with a $3.00 price target, TipRanks’ AI Analyst, Spark, assesses HUMA as "Neutral" due to financial and technical challenges, including lack of revenue and negative equity, despite some optimism for future growth from FDA approvals.
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
Humacyte, Inc. has secured a credit facility of up to $77.5 million with Avenue Venture Opportunities Fund II, L.P. The agreement includes an initial $40 million tranche, used to retire existing debt, and an additional two tranches totaling $37.5 million contingent on certain conditions. This financing is intended to support Humacyte's growth, including the expansion of Symvess and progress in clinical trials.
Humacyte Enters Sales Agreement with TD Securities
Humacyte (HUMA) has entered into a Sales Agreement with TD Securities (USA) LLC to offer and sell up to $60 million in common stock. The proceeds are designated for the commercialization of Symvess® for vascular trauma, further product pipeline development, and general corporate purposes. TipRanks' AI Analyst, Spark, assesses HUMA as Neutral, citing significant financial and technical challenges despite future growth potential from FDA approvals and product launches.
Humacyte secures $77.5 million loan facility
This article reports that Humacyte has secured a $77.5 million loan facility. Additional details about the loan, its purpose, and the terms are not available in the provided content.
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
Humacyte, Inc. has secured a credit facility of up to $77.5 million with Avenue Venture Opportunities Fund II, L.P., with an initial $40 million tranche used to retire existing debt. This non-dilutive financing is intended to support Humacyte's growth in 2026, including the expanded use of Symvess, interim results from a Phase 3 trial, and the first human study of its coronary tissue engineered vessel. Avenue Capital Group expressed enthusiasm for partnering with Humacyte to address significant patient needs.
Humacyte Secures $77.5 Million Credit Facility with Avenue Venture Opportunities Fund to Support Growth and Development Initiatives
Humacyte, Inc. has entered a credit facility agreement with Avenue Venture Opportunities Fund II, L.P., providing up to $77.5 million. An initial $40 million will retire existing debt, with an additional $37.5 million available pending certain conditions. This financing supports Humacyte's plans for expanding Symvess use and advancing clinical trials.
Humacyte (Nasdaq: HUMA) inks $77.5M Avenue credit deal, retires debt
Humacyte (Nasdaq: HUMA) has secured a credit facility of up to $77.5 million with Avenue Venture Opportunities Fund II, L.P., with an initial $40 million tranche used to retire existing debt. The four-year agreement provides non-dilutive financing for Humacyte as it advances Symvess commercialization, the V012 Phase 3 dialysis trial, and a first human coronary tissue engineered vessel (CTEV) study. Additional tranches totaling $37.5 million are contingent on revenue, regulatory approvals, and liquidity conditions.
Humacyte secures up to $77.5 million credit facility with Avenue Capital
Humacyte, Inc. (NASDAQ:HUMA) has secured a credit facility of up to $77.5 million with Avenue Venture Opportunities Fund II, L.P., aiming to address its significant cash burn challenges. The agreement includes an initial $40 million tranche to retire existing debt, with an additional $37.5 million available pending revenue, regulatory, and liquidity conditions. This financing comes after Humacyte received FDA approval for its Symvess product and despite a substantial stock price decline, analysts maintain a "Buy" consensus.
Humacyte Secures $77.5 Million Loan Facility
Humacyte, Inc. secured a senior secured term loan facility of up to $77.5 million, maturing on December 1, 2029, with Avenue Venture Opportunities Fund II, L.P. This financial arrangement aims to support Humacyte's operational needs and strategic goals. Despite financial and technical challenges and a neutral rating from TipRanks’ AI Analyst, Spark, the company is recognized for its focus on bioengineered human tissue development with potential for future growth.
